Life Science Pharmaceuticals, Inc. Enters Into Agreement With Abbott GmbH to Develop Antibody 806

November 17, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

GREENWICH, Conn.--(BUSINESS WIRE)--Life Science Pharmaceuticals, Inc. announced today that it has entered into a license agreement with Abbott to develop Antibody 806, which may prove to be an important tool in the fight against cancer.

Twitter
LinkedIn
Facebook
Email
Print

Alliances